A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
Strategic Collaboration with ARUP
17 July 2009
In July 2009 UCL announced a strategic collaboration and
training partnership with ARUP which follows closely on the important
strategic partnership announced this year with GlaxoSmithKline.
Alain Marcetteau, CEO of ARUP, has been a valued member of the UCL Research Challenges Board, set up in 2006. The UCL-ARUP Memorandum of Understanding is stimulating a number of initiatives.